Identifying Human Specific Adverse Outcome Pathways of Per- and Polyfluoroalkyl Substances Using Liver-Chimeric Humanized Mice
D. R. Robarts, D. Paine-Cabrera, M. Kotulkar, K. K. Venneman, S. Gunewardena, J. C. Corton, C. Lau, L. Foquet, G. Bial, U. Apte
This study uses liver-chimeric humanized mice to identify human-specific adverse hepatic effects of PFAS, finding NR1D1 inhibition as a common molecular mechanism.
bioRxiv · Feb 1, 2023 · PreprintPharmacology & Toxicology